Biotechnology

After game-changing FDA news for its Huntington's therapy, uniQure's upsized $225M offering signals massive investor confidence and accelerates its mission.

A novel drug designed by AI to prevent a crippling side effect of chemotherapy has received dual US and Taiwan regulatory approval, paving the way for human trials.

Beyond oil, Abu Dhabi is building a global life sciences hub. A new partnership with Sanofi to create a Vaccine Innovation Centre is its boldest move yet.

A new €35,000 grant fuels Canadian gut health research, highlighting a strategic play where corporate philanthropy meets a multi-billion dollar market.

A new partnership integrates AbTherx's elite Atlas™ mouse platform into FairJourney Bio's workflow, promising to slash timelines and boost success rates.

A Miami biotech is pioneering 'off-the-shelf' cell therapies to fight autoimmune and age-related diseases. Can they reset the body's own defenses?

With a $2.74M grant from The Michael J. Fox Foundation, biotech startup X-tosis is advancing a novel therapy that aims to fix the cell's failing powerhouses.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

A new alliance arms AI 'agents' with scientific reasoning and supercomputing power, aiming to make drug development faster, smarter, and more trustworthy.

The new SKyvec™ platform promises major productivity gains, positioning the CDMO giant to reshape a market desperate for manufacturing breakthroughs.

A new DOE-funded project pairs engineered microbes with AI to find critical minerals in hours, aiming to slash US foreign dependency and remake mining economics.

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

EpiVax's major lab expansion signals a pivotal shift in medicine, moving from flawed animal models to advanced tools that test drugs on human cells first.

The Oklahoma CDMO's move to integrate AI and 'high-touch' service isn't just a website refresh; it's a strategic play in a multi-billion dollar market.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

BioMendics secured a key FDA Fast Track designation for its EBS therapy, a strategic move that de-risks development and signals a new era for rare disease treatment.